Tag - KTTA

Pasithea Therapeutics (NASDAQ:KTTA) has announced safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from its Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid...